Tetracenomycins B3 and D3, besides tetracenomycin D (DO, were produced by a blocked mutant of the elloramycin producer Streptomyces olivaceus TU2353. The compounds were isolated as red powders, and their structures were elucidated by comparing their physicochemical data with those of the known tetracenomycins A2, Bl9 B2, D and E. Tetracenomycin B3 (2), the main compound, and tetracenomycin D (3) were antibiotically inactive against Gram-positive and Gram-negative bacteria, whereas tetracenomycin D3 (1) showed a moderate activity against Bacillus subtilis and Arthrobacter aurescens, Tetracenomycin B3 (2) is the key intermediate where the biosynthesis of the elloramycins branches off from the line leading to tetracenomycin C (5) as the final product of the tetracenomycin biosynthesis branch.
from the elloramycin producer S. olivaceus TU2353.
Strain TU 2353-R is characterized by a dark red discoloration of the growing medium. The analysis of the mycelium extract and culture filtrate by HPLCand diode array detection showed three peaks that were not identical with elloramycins in their retention times and UV/VISspectra. The similarity of the UV/VIS spectra of all three peaks ( Fig. 1 ) led to the assumption that the compounds were structurally related.
Fermentation and Isolation
To produce larger amounts of the tetracenomycins, 10-liter fermentations were performed. After drifting slightly into the acidic range, the pH rose to 8.25. The maximal tetracenomycin production AUG. 1988 was reached after 140 hours incubation time, at which the concentrations of the tetracenomycins were B3 (2) 555 mg/liter, D (3) 15 mg/liter and D3 (1) 134mg/liter.
Sixty % of the compounds was accumulated in the myceliumwhereas the rest was secreted into the culture medium.
The combined extracts from the mycelium (methanol -ammoniumhydroxide) and culture filtrate (butanol) contained 40 g of dry substance, which consisted of tetracenomycin B3 (2) 5.55 g, D (3) 0.15 g and D3 (1) 1.34 g, representing 17.6% of the crude material. The concentration of the combined extracts to the aqueous residue and extraction with petroleum benzene resulted in a reduction of the dry substance from 40 to 34 g without any loss of the tetracenomycins, which remained in the aqueous phase.
The isolation of 1 and 2 was achieved by chromatography of the crude material on Amberlite XAD-1180.After concentration and freeze-drying of the effluent, 27 g of a crude powder was obtained that contained 4.43 g of 2 and 1.13 g of 1. These two compounds were separated and purified by preparative medium-pressure liquid chromatography (MPLC) using a reversed-phase packing (particle size 25-40 jum). Per injection, 250 mg of the crude product were separated without loss of tetracenomycins into 41 mg of 2 and 10 mg of 1. After concentration and freeze-drying of the effluent, the two substances were obtained as red powders.
To isolate 3, the aqueous residue of the petroleum benzene extraction was extracted with butanol and the residue from this extract was chromatographed on silica gel. The crude powder (507 mg) contained 100 mgof 3 and was further purified by preparative reversed-phase MPLC.Per injection, 25 mg of the crude product could be separated without loss of tetracenomycin. After concentration and freeze-drying the compound was obtained as red powder.
Physico-chemical Properties The molecular formula of tetracenomycin B3, C21H14O8,was determined by high resolution analyses of the molecular ion (m/z 394) in its electron impact mass spectrum (EI-MS). Its structure is in accordance with formula 2 as proven by its NMRspectra (Tables 1 and 2 ) and by the fact that treating 2 with diazomethane at 0°C yields tetracenomycin A2 (4, TLC control). Both chelated OH groups can be observed in the *H NMRspectrum (d 12.30, 14.95) as well as the four aromatic protons, of which 2-H (8 6.72) and 4-H (8 7.08) show a meta coupling constant of 2.5 Hz. The free carboxyl group {d 187.8 in the 13C NMRspectrum) is also indicated by the broad absorption band between 2400 and 3400 cm"x and by the valence vibration at 1715cm-1 in the IR spectrum of 2. After treatment with diazomethane, the broad absorption band disappears and the carbonyl vibration band moves to 1740 cm-1, which is typical for esters.
The XHNMRspectrum of tetracenomycin D3 (1) shows a similar proton pattern as the one of 2, i.e. two chelated OHgroups at d 12.33 and d 15.16 and four aromatic protons, two of them (2-H d 6.61, and 4-H d 7.08) with a meta coupling of 3.5 Hz. But in contrast to 2, no OCH3signal is observable. The IR spectrum also shows a free carboxyl group as a broad absorption band between 2400 and 3400 cm"1. Because the substance is non-volatile, no molecular ion was detected in the EI-MS, but a peak mjz 318 indicated M+-CO2-H2Ofrom which a molecular formula of C20H12O8 for 1 was deduced. Treatment of 1 with diazomethane also yields tetracenomycin A2 (4). This was confirmed by the AHNMRspectrum, which showed three OCH3signals; and by the EI-MS, which showed a molecular ion at m/z 422, of which high resolution analysis proved the expected molecular formula of C23H18O8 (422.1002).
The third product was identified as tetracenomycin D (3) by high resolution analysis of its molecular ion in the EI-MS (m/z 336.0631, i.e. C19H12O6), by its NMRspectra (Tables 1 and 2) , and by the IR and the UVspectra, which were identical with those of an authentic sample.
Biological Activity 2 and 3 showed antimicrobial activity neither against Gram-positive nor Gram-negative bacteria tested by the broth dilution method and by an agar-plate diffusion assay. The antimicrobial spectrum of 1 is limited to an activity against Bacillus subtilis and Arthrobacter aurescens, as shown in Table 3 . In contrast to tetracenomycin C4), the elloramycins2>3) and the urdamycins7), the growth of streptomycete strains, including the producing organism, was insensitive to 1. Tetracenomycin B3 (2), the main compound of the tetracenomycin producing strain TU 2353-R was tested in the proliferation assay and the stem cell assay against LI210 leukemia cells, where a weak cytostatic effect was observed.
Discussion
As described in previous publications, the coupling of high-performance liquid chromatography with computer assisted diode array detection (HPLC/DAD)is a powerful tool for the identification of new microbial metabolites8~10). The comparison of the retention times and UV/VISspectra of the elloramycins, stored in an HPLC/DAD computer library, with those of the compounds produced by a blocked mutant of the elloramycin producer S. olivaceus confirmed the presence of three structurally related compoundsshowing distinct differences from the elloramycins.
Tetracenomycins B3 (2) and D3 (1) are two commonkey intermediates of the biosynthetic pathways to tetracenomycin C (5) and to the elloramycin family (6~9, Fig. 2 ). This confirms a biosynthetic hypothesis in which both compounds were suggested to be intermediates6-1. The branch leading to the elloramycins probably takes place on the stage of 2, because we found this compoundas a product of a blocked mutant of an elloramycin producer. The methylation sequence for the tetracenomycin C (5) biosynthesis leading from 1 was proposed to be first C-3 then C-86). But one cannot absolutely distinguish with physico-chemical methods between a methylation of 3-OH and 8-OH. Thus tetracenomycin D3 (1) and not B3 (2) might be the last common precursor of both pathways, if the structure of 2 were an 8-O-methyl ether instead of an 3-0-methyl ether. The latter assignment is more likely, however, because of the chemical shifts in the XHNMRspectrum of 2 ( Table 1 ). The biosynthetic sequence of the methylation reactions in case of the elloramycins (6~9) is impossible to establish because S. olivaceus TU 2353 produces elloramycins B (7), C (8) and D (9) side by side, which cannot derive from each other. For solving the methylation sequence problem of the tetracenomycin C (5) biosynthesis as well as for confirming all biosynthetic hypotheses in this context, we suggest to feed 14C labeled 1 and 2 to growing cultures of S. olivaceus TU 2353 and S. glaucescens TU49. The blocked mutant TU2353-R seems to be an ideal strain to produce these 14C enriched precursors via their biosynthesis from [14C]acetate.
Experimenta l Bacterial Strains
The producing organism TU 2353-R was obtained by UVmutagenesis from the elloramycin producing organism S. olivaceus TU2353. The strain was cultivated at 27°C in a mediumcontaining soy bean meal 2% and starch 2% (pH 7.0).
The standard strains for testing the biological activity spectrum were obtained from the stock culture collection of our laboratory or from ATCC.
Fermentati on
Strain TU 2353-R was cultivated in a 10-liter fermentor (NB 10, New Brunswick). Nine liters of medium containing soy bean meal 2% and starch 2% in tap water (pH 7) were inoculated with 1 liter of shaking cultures grown for 48 hours in the same medium. The fermentor was kept at 27°C and agitated at 220 rpm, with an aeration rate of 0.4 v/v/m. Isolation Hyphlo super-eel (3 %) was added to the fermentation broth (10 liters) which was then separated by multiple sheet filtration into biomass and culture filtrate. The mycelium was extracted 4 times with MeOH-25%ammoniumhydroxide (95 : 5), and the culture filtrate was extracted 4 times with butanol. The combined extracts from mycelium and culture filtrate were concentrated and extracted 3 times with petroleum benzene to remove lipophilic substances.
To isolate 1 and 2, the aqueous residue was chromatographed on a column containing Amberlite XAD-1180(70 x 8 cm i.d.). Impurities were washed out with acidic water (pH 4.5) and the tetracenomycins were eluted with MeOH. The separation of 1 and 2 was achieved by preparative MPLCusing glass columns (44 x 2.6 cm i.d., Biichi, Goppingen, FRG) filled with the reversed-phase packing HDSil 18-30-100 (Orpegen, Heidelberg, FRG). Both compounds could be quantitatively separated by linear gradient elution with 0.1 %aqueous acetic acid as solvent A and MeOHas solvent B, using a gradient profile from 50% B to 100% B within 45 minutes and flow rate of 30 ml/minute (Liquid Chromatograph SP-8000, Spectra-Physics, Darmstadt, FRG). The UVabsorbance of the eluate was monitored at 300 nm using a spectrophotometer equipped with a preparative cell (Knauer, Berlin, FRG).
To isolate 3, the aqueous residue of the petroleum benzene extraction was extracted 3 times with butanol. After concentration, the extract was chromatographed on a silica gel column (40 x 5 cm AUG. 1988 i.d., SI 60, 63-200 /^m, Merck, Darmstadt, FRG). 3 was eluted with dichloromethane-MeOH (8 : 2). Under these conditions, the compounds 1 and 2 were adsorbed on the silica gel and could be eluted by MeOH-ammonium hydroxide (95 :5). 3 was purified by preparative MPLCusing the same column as described for the compounds 1 and 2 by gradient elution from 70% aqueous MeOH to 100% MeOHwithin 28 minutes.
Biological Assays The broth dilution method was used to determine the MICof tetracenomycins. 105 cells/ml were used as inoculum, and growth inhibition was evaluated after incubation for 24 hours at 37°C on a rotary shaker.
The agar-plate diffusion assay was used to determine the antibacterial spectrum of tetracenomycins. The test solutions were applied to filter discs (6 mmdiameter) and the test plates were incubated for 24 hours at 37°C.
HPLC Analysis
The chromatographic system consisted of a HP-1090Mliquid chromatograph equipped with a diode array detection system (Hewlett-Packard, Waldbronn, FRG) ; a detection wavelength of 280 nm was used. 10 /4-samples were injected onto an HPLCcolumn (125 x4.6 mmi.d.), fitted with a guard column (20 x4.6 mmi.d.) which were packed with 5 jum Shandon Hypersil ODS(Grom, Ammerbuch, FRG). The samples were separated by gradient elution; solvent A was 0.1 %phosphoric acid, solvent B was acetonitrile. The linear gradient was from 20 to 100%solvent B in 10 minutes at a flow-rate of 2 ml/minute.
Structure Elucidation
The IR spectra were obtained in pressed KBr discs using a Perkin-Elmer Model 298 spectrometer. The NMRspectra were determined with a Yarian FT 80 (1.9 T) or XL 200 (4.7 T), respectively.
Chemical shifts (d in ppm) are reported relative to internal TMS. The multiplicities of the 13C NMRspectra were assigned by attached proton test (APT). The EI-MS (70 eV) were taken by a Varian MAT-31 1A mass spectrometer using a direct probe insert and high resolution analysis was done with perfluorokerosine as a standard. The UVspectrum was recorded using a Zeiss DMR21 spectrometer. TLC was performed on silica gel plates (Macherey & Nagel Sil G/UV 254+366, 0.25 mmsilica gel on glass). Tetracenomycin B3 (2): IR (KBr) cm"1 3420, 3400-2400 (br), 2920, 2850, 1715 (sh), 1670, 1620, 1585; EI-MS (70 eV) m/z 394 (49%, M+, high resolution calcd for C21H14O8 and found: 394.0689), 376 (100%, M-H2O), 350 (45%, M-CO2), 320 (18%), 174 (11%), 44 (96%); *H NMR (200MHz, DMSO-d6) see Table 1 ; 13C NMR (50.3 MHz, DMSO-c/6) see Table 2 . Tetracenomycin A2 (4) from Treatment of 1 with Diazomethane: 10 mg of tetracenomycin D3 were dissolved in 25 ml ethylene glycol monomethyl ether and cooled to 0°C. The solution was treated with an excess of diazomethane (5 equivalents of an etheric solution). The reaction started at once (discoloration from red to light orange) and was complete after 5 minutes. The only product 4 was purified by chromatography on Sephadex LH-20 (column 50 x 2.5 cm, CHC13 Table 2 .
